聚乙二醇化干扰素α-2a治疗HBeAg阳性慢性乙型肝炎40例临床疗效观察

Treatment Efficacy of Pegylated Interferon α-2a (PEGASYS) on HBeAg-positive Chronic Hepatitis B Patients

目的考察聚乙二醇干扰素α-2a（派罗欣）对HBeAg阳性慢性乙型肝炎患者的疗效。方法符合要求的慢性乙型肝炎患者40例,所有患者均使用派罗欣180ug皮下注射,1次/周,连续48周,治疗期间不使用其它抗病毒药物。选取肝功能、乙型肝炎病毒标志物、HBVDNA作为检测指标。结果治疗48周后,ALT/AST复常率72.5%（29/40）,HBsAg血清转换率12.5%（5/40）,HBeAg血清转换率45%（18/40）,HBVDNA转阴率65%（26/40）。结论派罗欣治疗慢性乙型肝炎能获得HBsAg血清转换,且安全性好。

Objective To study the treatment efficacy of pegylated interferon a -2a （PEGASYS） on HBeAg-positive chronic hepatitis B patients. Methods 40 patients with chronic hepatitis B were injected with PEGASYS 180ug, 1 times / week for 48 weeks.Hepatitis B virus, HBV DNA were selected as detection criterions. Results After 48 weeks of treatment, the ALT / AST normalization rate was 72.5% （29/40）; the HBsAg rate was12.5% （5 / 40）; the HBeAg seroconversion rates was 45% （18/40）, and the HBV DNA negative rate was 65% （26/40）. Conclusion The treatment of PEGASYS on the patients with chronic hepatitis B can get HBsAg seroconversion, and safety is good.